SCHEMBL802337

SCHEMBL802337

Cc1ccccc1-c1cc(-c2ccncc2)nc(Nc2n[nH]c3ccccc23)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 3/20 0.45
MAPK14 Q16539 1/20 0.41
CSF1R P07333 1/20 0.40
FADS1 O60427 2/20 0.39
ADRA2A P08913 2/20 0.39
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
TRPA1 O75762 1/20 0.38
WNT1 P04628 1/20 0.38
TGFBR1 P36897 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AURKA O14965 1/20 0.38
SRC P12931 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801694 0.92 VCP (0.43) GRM4FADS1ADRA2AALDH1A1CYP1A2
SCHEMBL12620024 0.84 USP1 (0.43) GRM4CSF1RFADS1ADRA2AALDH1A1
SCHEMBL801677 0.83 ALDH1A1 (0.46) GRM4MAPK14CSF1RFADS1ADRA2A
SCHEMBL802722 0.83 MAPT (0.36) ALDH1A1LMNACYP1A2CYP3A4ALOX15
SCHEMBL802027 0.81 FADS1 (0.46) GRM4FADS1ADRA2AALDH1A1LMNA
SCHEMBL802710 0.80 GSK3A (0.42) GRM4FADS1ADRA2AALDH1A1TRPA1
SCHEMBL802122 0.79 AURKA (0.49) CSF1RALDH1A1CLK4NPC1RAB9A
SCHEMBL802049 0.78 GRM4 (0.53) GRM4FADS1ADRA2AALDH1A1LMNA
SCHEMBL801700 0.78 FADS1 (0.43) GRM4FADS1ALDH1A1TRPA1WNT1
SCHEMBL802120 0.77 KDM4E (0.42) ALDH1A1LMNACYP1A2HSD17B10SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 GRM4 3726/4885MAPK14 657/4885CSF1R 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.